Traditional Chinese medicinal composition for treating phlegm-blood stasis syndrome type non-small cell lung cancer combined with hypercoagulable state

Abstract

The invention belongs to the technical field of medicines and particularly relates to a traditional Chinese medicinal composition for treating phlegm-blood stasis syndrome type non-small cell lung cancer combined with a hypercoagulable state. The traditional Chinese medicinal composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 4 to 8 parts of root of woodland beakchervil, 4 to 8 parts of root of aralia melanocarpa lauener, 4 to 8 parts of myriopteron extensum, 4 to 8 parts of embelia pauciflora diels, 4 to 8 parts of pilea peltata, 4 to 8 parts of cow pea pod, 4 to 8 parts of common dysosmatis rhizome and root, 4 to 8 parts of root of undulateleaf aralia, 4 to 8 parts of mango seed, 4 to 8 parts of radix seu caulis illigerae rhodanthae and 4 to 8 parts of licorice root. All medicinal materials are combined to jointly realize the efficacies of supplementing Qi and strengthening the body, and eliminating and resolving phlegm; the traditional Chinese medicinal composition tightly focuses on etiology and pathogenesis of the phlegm-blood stasis syndrome type non-small cell lung cancer combined with the high coagulation state; according to research results, it is found that the FBI (Fibrinogen), DD (D-Dimer) and FDP (Fibrinogen Degradation Product) levels can be reduced, so the traditional Chinese medicinal composition has a good effect for improving the high coagulation state of blood in non-small cell lung cancer patients.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a traditional Chinese medicine composition for treating non-small cell lung cancer with intermingled phlegm and blood stasis combined with hypercoagulable state. Background technique [0002] Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Clinical studies have found that NSCLC patients often have a hypercoagulable state of blood. The hypercoagulable state is not only the main cause of thrombotic diseases, but also promotes the growth and metastasis of lung cancer, and is an independent risk factor for the prognosis of lung cancer. Therefore, active prevention of blood hypercoagulability is a problem that cannot be ignored in the treatment of lung cancer. [0003] Western medicine believes that the hypercoagulable state of blood is mainly related to factors such as increased blood viscosity. Anti-platelet aggregation and blood lipid regul...

AI Technical Summary

Problems solved by technology

[0003] Western medicine believes that the hypercoagulable state of blood is mainly related to factors such as increased blood viscosity. It mainly reduces blood viscosity and relieves hypercoagulable state by anti-platelet aggregation and blood lipid regulation, but the clinical treatment effect is not good.

Images